Why Shares in Novo Nordisk Lost Weight Today

Shares in Denmark's pharmaceutical giant Novo Nordisk (NYSE: NVO) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with telehealth company Hims & Hers continues to escalate.

What happened

On Monday, Novo Nordisk terminated the partnership, claiming Hims & Hers "failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization'" and is "disseminating deceptive marketing."

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

It's a strong statement to make, and Hims & Hers management, led by CEO Andrew Dudum, isn't wasting any time in responding.

The argument centers around Novo Nordisk's weight loss drug, Wegovy. Novo Nordisk believes it had an agreement with Hims & Hers to stop the mass sales of compounded, copycat versions of Wegovy, but the latter failed to comply.

In response, Dudum gave an interview with Bloomberg and argued that Novo Nordisk had been pushing his company to guide patients toward Wegovy.

"They've been losing a tremendous amount of market share, there's been a huge amount of turmoil with management, and I think they're just under real financial strain to try to drive sales," Dudum said.

If Dudum's remarks were intended to hurt the stock price, then they arguably did their job today.

Image source: Getty Images.

What's next for Novo Nordisk?

The breakup of the relationship with Hims & Hers and subsequent remarks highlight the threat from competitors to Wegovy, like Eli Lilly's Zepbound. Still, Wegovy sales are growing at a whopping rate (up 85% in the first quarter on a reported basis), and there's enough growth in the market for everyone.

Should you invest $1,000 in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $906,556!*

Now, it’s worth noting Stock Advisor’s total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 23, 2025

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.